AK112 Injection clinical trials

Phase III Study of AK112 for NSCLC Patients

This study looks at a new drug, AK112, combined with standard chemotherapy for a type of lung cancer. It's for people whose cancer has progressed after previous targeted treatment. We want to see if this combination gives better results than chemotherapy alone.